Navigation Links
Medgenics Announces Positive Data From Phase I/II Clinical Trial of EPODURE Treatment of Anemia in Chronic Kidney Disease
Date:2/3/2009

-- EPODURE Biopump demonstrates safety and efficacy for four months with

single administration

-- Institutional Review Board confirms safety and efficacy of low dose and

approves continuation of trial with higher doses

-- Biopump may offer alternative to months of expensive injections

MISGAV, Israel and LONDON, Feb. 3 /PRNewswire/ -- Medgenics (AIM: MEDU/MEDG), today announced that the EPODURE Biopump, the Company's unique tissue-based technology, has successfully demonstrated safety and efficacy for the sustained protein therapy of anemia in patients with chronic kidney disease (CKD).

In the Company's ongoing Phase I/II clinical trial, a one-time administration of EPODURE, producing and delivering the low dose of 18-25 IU/kg/day of the protein erythropoietin (EPO), was sufficient to sustain therapeutic elevation of hemoglobin in most patients. The earliest patients to receive treatment have shown sustained hemoglobin within the target range for four months without receiving any EPO injections. By contrast, in standard practice today, EPO injections are required up to several times per week, and the comparable low dose does not result in sufficient hemoglobin levels in most patients.

By having maintained hemoglobin levels in the target range for several months in more than one patient, the study has already demonstrated that when administered at an appropriate dose for the patient, EPODURE can provide sustained anemia treatment for at least four months while alleviating the need for frequent EPO injections.

The Phase I/II clinical trial was approved for three escalating dose groups, beginning with six patients at the lowest dose, and called for a safety review after treatment of these first six patients prior to treatment using higher doses. The Institutional Review Board (IRB) of Hadassah Hebrew University Hospital in
'/>"/>

SOURCE Medgenics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Oridion Announces Significant Medical Studies Presented at STA
2. ThermoGenesis Announces MXP Involvement in New Regenerative Medicine Initiatives
3. British Midlands University Announces Use of Gene Technology to Fight Lethal Hospital Acquired Infection
4. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
5. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
6. Impact Medical Solutions Announces Appointment of New Director and Corporate Update
7. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
8. ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
9. Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer
10. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
11. Kyowa Hakko Kirin Announces Development Policy for Anti-Parkinsons Disease Drug KW-6002 (Istradefylline)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... 26, 2011 Galleon Pharmaceuticals, a leader in the ... board of directors has elected Thomas J. Dietz, Ph.D., ... CEO of Waypoint Holdings, LLC, a diversified financial-holdings and ... was co-CEO and then CEO and a director of ...
... Oct. 26, 2011 Reportlinker.com announces that ... in its catalogue: Wheelchair ... to 2015 http://www.reportlinker.com/p0157387/Wheelchair-Market-Shares-Strategies-and-Forecasts-Worldwide-2009-to-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... 484 pages, 235 tables and figures. Worldwide ...
Cached Medicine Technology:Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals 2Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 2Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 3Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 4Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 5Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 6Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 7Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 8Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 9Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 10Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 11Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 12Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 13Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 14Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 15Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 16Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 17Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 18Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 19
(Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
(Date:4/18/2014)... new study in the American Journal of Preventive ... reveals a recurring pattern that could be leveraged to ... San Diego State University, the Santa Fe Institute, Johns ... searches (searches that included the term healthy and were ... from 2005 to 2012. They found that on average, ...
(Date:4/17/2014)... inflammation in non-cancerous prostate tissue may have nearly twice ... with no inflammation, according to results of a new ... Cancer Center. , The link between persistent inflammation and ... prostate cancer those with a Gleason score between ... most aggressive and rapidly growing prostate cancers. , "What ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
(Date:4/17/2014)... review published in the April issue of Immunity ... Institute for Medical Research, says it,s time to take ... to treating sepsis, which kills millions worldwide every ... when molecules released into the bloodstream to fight an ... is necessary for maintaining good health without inflammation, ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
... care to properly heal , ... ... On the one-year anniversary of the massive earthquake that devastated ... education and humanitarian assistance organization, is officially launching the China ...
... Health Organization urge vigilance against the "swine flu" (Type A influenza ... Huff, recommends practical tips for protecting your young child and baby ... ... Asheville, NC (PRWEB) May 12, 2009 -- The World Health Organization ...
... Chairman of the,Avon Foundation for Women, today joined ... Women leaders for a day of events to ... Breast Center at the San,Francisco General Hospital and ... making progress possible in breast cancer research and,care. ...
... Tenn., May 11 Brookdale Senior Living Inc. (NYSE: ... Executive Officer, and Mark Ohlendorf, Co-President and Chief Financial Officer, ... of America and Merrill Lynch 2009 Health Care Conference in ... 10:00 a.m. Eastern Time.The presentation is being audio webcast live ...
... Entity for Topical Acne Treatment in a DecadeCARLSBAD, Calif., May ... entered into a co-promotion agreement with Allergan for ACZONE(R) ... Representing the first new molecule in a decade approved by ... 12 years of age and older, ACZONE(R) Gel 5% combines ...
... following statement is from Regence BlueCross BlueShield President and CEO ... by a group of private-sector health industry leaders to decrease ... as much as $2 trillion over the next ten years:"I ... costs in our nation. We are a country that ...
Cached Medicine News:Health News:Project HOPE Launches Rehabilitation Program to Address Needs of Thousands Recovering from Injuries Sustained During the May 12, 2008 Earthquake 2Health News:Project HOPE Launches Rehabilitation Program to Address Needs of Thousands Recovering from Injuries Sustained During the May 12, 2008 Earthquake 3Health News:Protect Your Young Child And Baby From "Swine Flu" In Four Easy Steps 2Health News:Protect Your Young Child And Baby From "Swine Flu" In Four Easy Steps 3Health News:MultiVu Video Feed: REESE WITHERSPOON JOINS AVON FOUNDATION FOR WOMEN AND SAN FRANCISCO GENERAL HOSPITAL TO CELEBRATE 5TH ANNIVERSARY OF AVON COMPREHENSIVE BREAST CENTER 2Health News:SkinMedica to Co-Promote ACZONE(R) (dapsone) Gel 5% to Pediatricians in the U.S. 2Health News:SkinMedica to Co-Promote ACZONE(R) (dapsone) Gel 5% to Pediatricians in the U.S. 3Health News:SkinMedica to Co-Promote ACZONE(R) (dapsone) Gel 5% to Pediatricians in the U.S. 4Health News:Regence Optimistic About Health Industry Leaders' Pledge to Cut Health Care Costs 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: